All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.

  TRANSLATE

The lym Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the lym Hub cannot guarantee the accuracy of translated content. The lym and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

The Lymphoma & CLL Hub is an independent medical education platform, sponsored by AbbVie, BeOne Medicines, Johnson & Johnson, Roche, and Sobi, and supported through educational grants from Bristol Myers Squibb, Incyte, Lilly, and Pfizer.   View funders.

Now you can support HCPs in making informed decisions for their patients

Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.

Find out more

Subcutaneous rituximab recommended for approval by FDA’s ODAC in Follicular Lymphoma, Diffuse Large B-Cell Lymphoma, and Chronic Lymphocytic Leukemia

By Terri Penfold

Share:

Apr 4, 2017


A novel, subcutaneous (SC) co-formulation of rituximab and hyaluronidase (which aids delivery of medicine beneath the skin) has been unanimously (11 vs 0) recommended for approval by the U.S. Food and Drug Administration’s (FDA’s) Oncologic Drugs Advisory Committee (ODAC).

The indications proposed for Genentech’s SC rituximab treatment include: Newly Diagnosed (ND) DLBCL and FL, as well as Relapsed/Refractory (R/R) FL, low grade Lymphoma, and CLL.

ODAC’s recommendation is based on results of five clinical trials, including a total of 2,000 patients with a range of hematological malignancies:

  • SparkThera (NCT00930514); phase Ib maintenance study in ND or R/R FL
  • SABRINA (NCT01200758); phase III induction and maintenance study in ND FL
  • SAWYER (NCT01292603); phase Ib study in ND CLL
  • MabEase (NCT01649856); phase III study in ND DLBCL
  • PrefMab (NCT01724021); phase III patient preference study in ND FL and DLBCL

Overall, the results show that the efficacy, safety, and pharmacokinetics of SC versus IV rituximab are non-inferior.

Key Highlights:

MabEase trial
  • Evaluated SC (n = 381) versus IV (n = 195) rituximab combined with CHOP chemotherapy
  • ORR = 71.8% in IV arm versus7% in SC arm
  • CR = 42.1% in IV arm versus0% in SC arm
  • HR for PFS = 1.23 (95% CI, 0.86–1.76; P = 0.280); HR for OS = 1.06 (95% CI, 0.68–1.65; P = 0.717)
SABRINA trial
  • Evaluated SC (n = 205) versus IV (n = 205) rituximab combined with CHOP or CVP chemotherapy
  • ORR = 84.9% in IV arm versus 4% in SC arm (P = 0.8911)
  • CR = 32.2% in IV arm versus2% in SC arm
  • HR for PFS = 0.84 (95% CI, 0.57–1.23; P = 0.3696); HR for OS = 0.81 (95% CI, 0.42–1.57; P = 0.5398).
SAWYER trial
  • Compared SC (n = 88) versus IV (n = 88) rituximab in combination with chemotherapy
  • ORR = 80.7% in IV arm versus 2% in SC arm (P = 0.4227)
  • CR = 33% in IV arm versus1% in SC arm
  • HR for PFS = 0.89 (95% CI, 0.49–1.64; P = 0.7192); HR for OS = 0.60 (95% CI, 0.24–1.52; P = 0.2789)

A final approval decision is expected from the FDA by June 26 2017. SC rituximab has been available in Europe as MabThera (SmPC) since 2014. The IV rituximab formulation currently holds FDA approval for ND FL, ND DLBCL, R/R low grade or FL, and ND and R/R CLL (PI).

 

References

Your opinion matters

Which of the following would most increase your confidence in referring patients with R/R large B-cell lymphoma for CAR T-cell therapy?